Rays Power Infra announced closure of INR 127 Crore Equity Capital Fund Raise - Godrej Agrovet Reiterates its Commitment to Handhold Indian Farmers on Kisan Diwas - "Mother's Embrace" A Photography Exhibition will be displayed by Renowned Photographer Devendra Naik at Jehangir Art Gallery in Mumbai - DAM Capital Advisors collects Rs 251 cr from Anchor Investors - Blackstone backed Ventive Hospitality Limited raises ₹ 719.55 Crores from 26 anchor investors at the upper end of the price band at ₹643 per equity share - The Inventurus Knowledge Solutions Limited listing ceremony held at NSE today - “ENCOUNTER WITH THE MOMENT” An Exhibition of Photographs by Gurdeep Dhiman at Jehangir Art Gallery in Mumbai - VENTIVE HOSPITALITY LIMITED ANNOUNCED ITS Rs. 16,000 MILLION INITIAL PUBLIC OFFERING (IPO) TO OPEN ON FRIDAY, DECEMBER 20, 2024 Sets Price Band fixed at Rs. 610 to Rs. 643 per equity share of face value of Rs. 1 each - Dr Agarwals Eye Hospital, Chembur, launches advanced laser system for precise and bladeless corneal surgery, Renowned actress Saiee Manjrekar inaugurates the state-of-the-art WaveLight FS200 Femtosecond Laser System - DAM Capital Advisors Limited announced its initial public offering (IPO) to open on Thursday, December 19, 2024 Sets Price Band fixed at ₹ 269/- per equity share to ₹ 283/- per equity share of the face value of ₹2 each - TRANSRAIL LIGHTING LIMITED ANNOUNCED ITS INITIAL PUBLIC OFFERING (IPO) TO OPEN ON THURSDAY, DECEMBER 19, 2024 Sets Price Band has been fixed at ₹ 410.00 to ₹ 432.00 per equity share, of face value ₹2 each

Kotak Mahindra Capital Company Associates with Ignite Life Science Foundation for Research in Antimicrobial Resistance

Mumbai, 26th June 2023 (GNI): Under its corporate social responsibility (CSR) initiative, Kotak Mahindra Capital Company Ltd (“KMCC” / “Kotak Investment Banking”) today announced its association with Ignite Life Science Foundation (ILSF) for supporting research in the area of Antimicrobial Resistance (AMR).

The Bengaluru-based not-for-profit foundation, ILSF aims to leverage scientific discoveries for social good. The COVID-19 pandemic unmasked the growing problem of AMR in India, which can’t be solved through expensive antimicrobial drugs that are being developed. The country needs cheaper and more effective solutions that can minimise antimicrobial drug usage in all environments, including in agriculture. Solutions for AMR can come from new knowledge about resistance mechanisms in microorganisms and diagnostic methods to rapidly identify the organism causing an infection.

Ramesh Srinivasan, MD & CEO, Kotak Mahindra Capital Company said, “Our CSR Project on Healthcare includes preventive healthcare and sanitation. We are pleased to associate with Ignite Life Science Foundation to provide CSR funding for research in the area of Antimicrobial Resistance. We believe that our CSR project is likely to produce outcomes that are of immense benefit, given the scale and importance of these problems for human health.”

Dr. T. S. Balganesh, President of GangaGen Biotechnologies Pvt Ltd and a member of the Scientific Advisory Board of Ignite Life Science Foundation said, “Antimicrobial Resistance is on the verge of upsetting all the gains that we have made with modern medicine. Novel therapeutics aimed to address this global and local problem is urgently needed as a part of the ‘one health’ concept for sustaining our race. AMR is a priority area under India’s G-20 presidency. Increasing our collective effort through funding for research, awareness and stewardship will surely make an impact towards combating this potential ‘pandemic’.”

KMCC’s CSR Project will act as a triaging and a support mechanism to ensure that good ideas in the field of AMR thrive to a stage where they can be worked on by industry partners or collaborators.

Kotak Karma is the Corporate Social Responsibility (CSR) identity of Kotak Mahindra Group.ends GNI

Be the first to comment on "Kotak Mahindra Capital Company Associates with Ignite Life Science Foundation for Research in Antimicrobial Resistance"

Leave a comment

Your email address will not be published.


*